Cefonicid

Cefonicid is a long-acting cephalosporin antibiotic. Cefonicid also acts as a noncompetitive class I β-lactamase inhibitor with a K_i value of 0.8 μM. Cefonicid exhibits broad-spectrum antimicrobial activity and is effective against a variety of Gram-positive and Gram-negative bacteria. Cefonicid can be used for research on infections^[1][2][3][4]. In Vitro:Cefonicid (25-200 mg/L; 3-6 days) dose-dependently inhibits the proliferation of human PBMCs stimulated by FLU, XENO, ALLO, and PHA (HY-N7038)^[1].
Cefonicid (0-200 mg/L; 7 days) dose-dependently inhibits IL-2 production by human PBMC stimulated with FLU, XENO and ALLO^[1].
Cefonicid (0-24 h) exhibits concentration-dependent bactericidal activity against Klebsiella pneumoniae strain 2603 in vitro, with an MIC of 0.25 mg/L^[3]. In Vivo:Cefonicid (15 mg/kg; i.p.; 2 doses) significantly reduces the pulmonary bacterial load in guinea pigs infected with K. pneumoniae^[3].
Cefonicid (40 mg/kg; single dose) exhibits excellent protective effects against S. aureus, E. coli, P. mirabilis, and K. pneumoniae infections in mice^[4].
Cefonicid exerts excellent preventive protective effects against surgical wound infections in mice, with an ED₅₀ value of ≤2.1 mg/kg against Gram-negative bacilli and an ED₅₀ value ranging from 3.7 to 8.7 mg/kg against S. aureus^[4].